According to MedPage Today (4/6, Monaco, Monaco), certain “anticonvulsant mood stabilizers may increase the risk for developing type 2 diabetes (T2D),” researchers concluded in a study that analyzed commercial health insurance data from “274,206 [people] ages 20 to 65 (adults) and 74,005 [people] ages 10 to 19 years (children).” The study revealed that “among adults who initiated an anticonvulsant mood stabilizer, treatment with valproate was tied with a 1.17% higher adjusted risk difference for developing T2D over five years compared with lamotrigine (Lamictal),” whereas “carbamazepine (Tegretol) and oxcarbazepine (Trileptal, Oxtellar XR)…didn’t have the significantly higher five-year T2D risk difference compared with lamotrigine.” The findings were published online April 6 in JAMA Network Open.
Related Links:
— MedPage Today (requires login and subscription)